Transplantationstechnologien und Forschung

These patients face a delicate balance as HSCT suppresses their immune system to prevent disease relapse but leaves them vulnerable to infections, including the novel coronavirus. The knowledge gap concerning the impact of COVID-19 on HSCT recipients with ADs is particularly concerning. While there is a wealth of information on COVID-19 outcomes in the general population and even in patients with other underlying conditions, this specific subgroup remains largely uncharted territory. Data on the severity, progression, and ultimate outcomes of COVID-19 in these individuals are still sorely lacking. In an effort to address this void, we present a summary of eleven cases in which individuals who had undergone HSCT for ADs contracted COVID-19. These cases offer valuable insights into the potential risks, disease course, and outcomes.